Recombinant Proteins Market Overview, Key Trends, and Major Player Analysis

The recombinant proteins industry is set for a remarkable surge in the coming years, driven by innovations and expanding applications across biotechnology and pharmaceuticals. As the sector evolves, several key factors, players, and trends are shaping its trajectory, offering promising opportunities and challenges alike.

Projected Market Value and Expansion of the Recombinant Proteins Industry
The recombinant proteins market is anticipated to experience rapid growth, reaching a valuation of $4.84 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 13.7%. Several elements are contributing to this robust growth forecast, including the rising adoption of next-generation biologics, increased investments in biomanufacturing infrastructure, and a growing demand for personalized therapeutic solutions. Additionally, the development of biosimilars and the widespread use of recombinant proteins in research activities are significant growth drivers. Prominent trends expected to shape the market include increased production of therapeutic antibodies, heightened demand for recombinant enzymes, advances in protein engineering techniques, expansion of biologics manufacturing capabilities, and a stronger emphasis on expressing proteins with high purity.

Download a free sample of the recombinant proteins market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9959&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Key Companies Emerging in the Recombinant Proteins Market
A number of influential companies are currently active within the recombinant proteins sector. Leading players include Abcam plc, Abnova Corporation, Bio-Rad Laboratories Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen-Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., and Eli Lilly and Company.

Strategic Acquisition Strengthening Recombinant Protein Capabilities
In May 2024, Sanofi, the global healthcare giant based in France, acquired Inhibrx, Inc., a US biopharmaceutical company specializing in recombinant protein therapeutics and engineered biologics for rare diseases and oncology. This acquisition, valued at approximately $1.7 billion plus a contingent value right, enhances Sanofi's recombinant protein portfolio. It also provides access to SAR447537, a novel human recombinant protein designed to treat alpha-1 antitrypsin deficiency (AATD). This move broadens Sanofi's rare disease expertise and deepens its biologics pipeline, reinforcing its commitment to innovative therapeutic development.

View the full recombinant proteins market report:
https://www.thebusinessresearchcompany.com/report/recombinant-proteins-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Collaborations and Partnerships Catalyzing Recombinant Protein Innovation
Collaborative ventures are becoming increasingly common among recombinant protein companies as they seek to strengthen market positions and accelerate innovation. For example, in October 2023, ARTES Biotechnology GmbH from Germany partnered with Basic Pharma, a pharmaceutical firm based in the Netherlands. This partnership includes a strategic alliance and co-marketing agreement focused on producing non-GMP recombinant proteins. Their goal is to optimize supply chain processes, reducing time-to-market for new pharmaceutical products and enhancing efficiency in development and production.

Comprehensive Segmentation of the Recombinant Proteins Market
The recombinant proteins market is categorized into various segments for a detailed understanding of its scope. These segments include:
1) Product types such as antibodies, cytokines, virus antigens, enzymes, recombinant regulatory proteins, hormones, and other related products.
2) Applications covering drug and discovery development, therapeutics, research, and other uses.
3) End-user groups including pharmaceutical and biotechnology companies, academic and research institutions, diagnostic laboratories, and other users.

Further breakdowns within product categories feature monoclonal and polyclonal antibodies; interleukins, interferons, and tumor necrosis factors under cytokines; viral capsid and envelope proteins among virus antigens; various enzymes like restriction enzymes, polymerases, and ligases; transcription factors and receptors as recombinant regulatory proteins; insulin and growth hormones; and fusion proteins and peptide therapeutics among other products.

This detailed segmentation supports a nuanced view of the recombinant proteins industry, highlighting key areas of focus and potential growth opportunities through 2030.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.